Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579977 · ClinicalTrials.gov registry record · Phase 2
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 902
- Enrollment target
NCT05579977 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 902 participants.
The verdict
NCT05579977, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 902 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Rybelsus. Those in the obesity part of the study, will receive either active study drug or placebo. The study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between.
Interventions
- OTHER Placebo
- DRUG PF-07081532
- DRUG Rybelsus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 2022-10-27 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05579977
The ClinicalTrials.gov registry entry for NCT05579977 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 902 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05579977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05579977 about?
NCT05579977 is a clinical study titled "Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity". The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals...
What is the current status of trial NCT05579977?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 902 participants. The study started on 2022-10-27. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT05579977?
The interventions under investigation include: Placebo (OTHER), PF-07081532 (DRUG), Rybelsus (DRUG).
Who is sponsoring clinical trial NCT05579977?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.